Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Lung Neoplasms 7 Brain Neoplasms 5 Meningeal Carcinomatosis 2 Recurrence 1 Rare Tumor 1 Radiation Pneumonitis 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 NSCLC 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1 Carcinoma 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 46 Carboplatin 43 pembrolizumab 39 Paclitaxel 38 Gemcitabine 27 Radiotherapy 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 18 Radiotherapy, Intensity-Modulated 17 Docetaxel 17 Cetuximab 16 Specimen Handling 15 Nivolumab 15 Cyclophosphamide 14 durvalumab 13 Fluorouracil 13 Sorafenib 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 10 Sunitinib 9 Platinum 9 osimertinib 8 Radiation 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Capecitabine 8 1,2-diaminocyclohexaneplatinum II citrate 8 Ipilimumab 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡